Tab navigation

tab1

Cancer is one of the most prominent health challenges we face today. In 2018, it is estimated that 18 million persons were diagnosed with cancer world-wide. In China, the age standardisation rate for cancer was a little over 200 per 100,000 inhabitants – a figure likely to grow significantly as the population ages.

With China's rapidly ageing population and shifts in lifestyle, rates of cancer and other non-communicable diseases are steeply on the rise. Consumers are increasingly looking for solutions to cope with the risk of cancer and sales of critical illness products have increased sharply in China.

This is a great opportunity for insurers but not one without risk. While medical and technological advancements have made access to cancer screening and early detection more convenient for consumers, are insurers ready to manage the potential implications of asymmetrical information disclosure? Are health and medical service providers ready to cope with rising demand for cancer treatment?

Join Swiss Re Institute in Beijing to discuss with medical experts, health service administrators, regulators and peer insurance professionals on the upcoming challenges and opportunities in building stronger societal resilience to fight cancer risk in China. As China embarks on its Healthy China 2030 national health policy, the insurance industry will have a pivotal role to play in closing the health protection gap together.

Contact